RT Journal Article
SR Electronic
T1 Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.14.21264959
DO 10.1101/2021.10.14.21264959
A1 de Gier, Brechje
A1 Andeweg, Stijn
A1 Backer, Jantien A.
A1 ,
A1 Hahné, Susan J.M.
A1 van den Hof, Susan
A1 de Melker, Hester E.
A1 Knol, Mirjam J.
YR 2021
UL http://medrxiv.org/content/early/2021/10/14/2021.10.14.21264959.abstract
AB We estimated vaccine effectiveness against onward transmission by comparing secondary attack rates among household members between vaccinated and unvaccinated index cases, based on source and contact tracing data collected when Delta variant was dominant. Effectiveness of full vaccination of the index against transmission to fully vaccinated household contacts was 40% (95% confidence interval (CI) 20-54%), which is in addition to the direct protection of vaccination of contacts against infection. Effectiveness of full vaccination of the index against transmission to unvaccinated household contacts was 63% (95%CI 46-75%). We previously reported effectiveness of 73% (95%CI 65-79%) against transmission to unvaccinated household contacts for the Alpha variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Dutch Ministry of Health, Welfare and Sports.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise at the RIVM assessed the research proposal. They verified whether the work complies with the specific conditions as stated in the law for medical research involving human subjects (WMO), and were of the opinion that the research does not fulfill one or both of these conditions and therefore conclude it is exempted for further approval by the ethical research committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available.